27423449|t|Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?
27423449|a|New chemotherapeutic regimens have improved survival for stage IV pancreatic ductal adenocarcinoma and occasionally major response of liver metastases can be observed. Aim of this work is to analyze the outcomes of patients undergoing primary chemotherapy for liver metastases from pancreatic cancer and to evaluate the results of surgical resection. Retrospective analysis. patients with extra-hepatic metastases, patients with Eastern Cooperative Oncology Group performance status â‰¥3, patients undergoing supportive care alone. 127 patients were identified. Liver metastases were unilobar in 28.5% of patients. Chemotherapy regimens included gemcitabine alone or in association with other agents (44%), oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX 8%), and cisplatin, gemcitabine plus capecitabine and epirubicin (PEXG) or capecitabine and docetaxel (PDXG) or epirubicin and fluorouracil (PEFG) (48%). 56 patients (44%) had a complete (7%) or partial response (37%). surgical resection was carried out in 11 patients (8.5%). Median overall survival was 11 months for the entire cohort and 15 months for those with partial / complete response. In this sub-group median survival was significantly longer (46 versus 11 months) for patients undergoing resection (P < 0.0001). Independent predictors of overall survival were chemotherapy with multiple agents (HR: 0.512), surgical resection (HR: 0.360), >5 liver metastases at diagnosis (HR: 3.515), and CA 19.9 reduction < 50% of baseline value (HR: 2.708). Surgical resection of primary pancreatic tumor with or without residual liver disease can be considered in selected cases after primary chemotherapy and it is associated with improved survival.
27423449	20	38	surgical resection	T058	UMLS:C0728940
27423449	56	73	pancreatic cancer	T038	UMLS:C0030297
27423449	79	95	liver metastases	T038	UMLS:C0494165
27423449	110	122	chemotherapy	T058	UMLS:C3665472
27423449	128	153	chemotherapeutic regimens	T058	UMLS:C0392920
27423449	181	189	stage IV	T170	UMLS:C0441772
27423449	190	222	pancreatic ductal adenocarcinoma	T038	UMLS:C1335302
27423449	246	254	response	T033	UMLS:C1704632
27423449	258	274	liver metastases	T038	UMLS:C0494165
27423449	367	379	chemotherapy	T058	UMLS:C3665472
27423449	384	400	liver metastases	T038	UMLS:C0494165
27423449	406	423	pancreatic cancer	T038	UMLS:C0030297
27423449	431	439	evaluate	T058	UMLS:C0220825
27423449	444	451	results	T033	UMLS:C0456984
27423449	455	473	surgical resection	T058	UMLS:C0728940
27423449	475	497	Retrospective analysis	T062	UMLS:C0035363
27423449	513	526	extra-hepatic	T082	UMLS:C0205054
27423449	527	537	metastases	T038	UMLS:C0027627
27423449	553	606	Eastern Cooperative Oncology Group performance status	T201	UMLS:C1520224
27423449	631	646	supportive care	T058	UMLS:C0344211
27423449	684	700	Liver metastases	T038	UMLS:C0494165
27423449	737	758	Chemotherapy regimens	T058	UMLS:C0392920
27423449	768	779	gemcitabine	T103	UMLS:C0045093
27423449	815	821	agents	T103	UMLS:C0450442
27423449	829	840	oxaliplatin	T103	UMLS:C0069717
27423449	842	852	irinotecan	T103	UMLS:C0123931
27423449	854	866	fluorouracil	T103	UMLS:C0016360
27423449	871	881	leucovorin	T103	UMLS:C0023413
27423449	883	893	FOLFIRINOX	T058	UMLS:C0879464
27423449	903	912	cisplatin	T103	UMLS:C0008838
27423449	914	925	gemcitabine	T103	UMLS:C0045093
27423449	931	943	capecitabine	T103	UMLS:C0671970
27423449	948	958	epirubicin	T103	UMLS:C0014582
27423449	960	964	PEXG	T058	UMLS:C0392920
27423449	969	981	capecitabine	T103	UMLS:C0671970
27423449	986	995	docetaxel	T103	UMLS:C0246415
27423449	997	1001	PDXG	T058	UMLS:C0392920
27423449	1006	1016	epirubicin	T103	UMLS:C0014582
27423449	1021	1033	fluorouracil	T103	UMLS:C0016360
27423449	1035	1039	PEFG	T058	UMLS:C0392920
27423449	1097	1105	response	T033	UMLS:C1704632
27423449	1113	1131	surgical resection	T058	UMLS:C0728940
27423449	1224	1230	cohort	T098	UMLS:C0599755
27423449	1279	1287	response	T033	UMLS:C1704632
27423449	1297	1306	sub-group	T170	UMLS:C1515021
27423449	1394	1403	resection	T058	UMLS:C0728940
27423449	1466	1478	chemotherapy	T058	UMLS:C3665472
27423449	1493	1499	agents	T103	UMLS:C0450442
27423449	1513	1531	surgical resection	T058	UMLS:C0728940
27423449	1548	1564	liver metastases	T038	UMLS:C0494165
27423449	1568	1577	diagnosis	T033	UMLS:C0011900
27423449	1595	1602	CA 19.9	T058	UMLS:C0201551
27423449	1650	1668	Surgical resection	T058	UMLS:C0728940
27423449	1680	1696	pancreatic tumor	T038	UMLS:C0030297
27423449	1722	1735	liver disease	T038	UMLS:C0023895
27423449	1786	1798	chemotherapy	T058	UMLS:C3665472
27423449	1825	1833	improved	T033	UMLS:C0184511